KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Intangibles: 2022-2025

Historic Intangibles for Halozyme Therapeutics (HALO) over the last 4 years, with Sep 2025 value amounting to $348.5 million.

  • Halozyme Therapeutics' Intangibles fell 16.93% to $348.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $348.5 million, marking a year-over-year decrease of 16.93%. This contributed to the annual value of $401.8 million for FY2024, which is 15.02% down from last year.
  • Halozyme Therapeutics' Intangibles amounted to $348.5 million in Q3 2025, which was down 4.85% from $366.3 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Intangibles peaked at $976.1 million during Q2 2022, and registered a low of $348.5 million during Q3 2025.
  • Over the past 3 years, Halozyme Therapeutics' median Intangibles value was $437.4 million (recorded in 2024), while the average stood at $437.8 million.
  • Data for Halozyme Therapeutics' Intangibles shows a maximum YoY crashed of 48.29% (in 2023) over the last 5 years.
  • Halozyme Therapeutics' Intangibles (Quarterly) stood at $546.7 million in 2022, then dropped by 13.50% to $472.9 million in 2023, then decreased by 15.02% to $401.8 million in 2024, then decreased by 16.93% to $348.5 million in 2025.
  • Its last three reported values are $348.5 million in Q3 2025, $366.3 million for Q2 2025, and $384.1 million during Q1 2025.